Industry Encore Posters

JL1001E: Adoption and early clinical outcomes of atezolizumab (atezo) + carboplatin and etoposide (CE) in patients with extensive-stage small cell lung cancer (ES-SCLC) in the real-world (RW) setting

JL1002E: Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in SPARTAN and TITAN studies

JL1003E: Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up results from the JAVELIN Bladder 100 trial

JL1004E: Clinical Outcomes of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) with Prostate-Specific Antigen (PSA) Decline to Undetectable Levels on Enzalutamide (ENZA): Post Hoc Analysis of ARCHES

JL1005E: Clinical Strategies for Mitigation of Cytokine Release Syndrome and Neurotoxicity With Chimeric Antigen Receptor T Cell Therapy Ciltacabtagene Autoleucel in Multiple Myeloma

JL1006E: Cost-effectiveness of atezolizumab for adjuvant treatment of patients with stage II-IIIA PD-L1+ non-small cell lung cancer

JL1009E: Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1

JL1010E: Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents

JL1011E: EPIK-B4: a phase 2, randomized study of metformin (MET) extended release (XR) +/− dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL)

JL1012E: Estimating Recurrences Prevented and Costs Avoided with Atezolizumab in Early Non-Small Cell Lung Cancer in the United States

JL1014E: First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): phase 1/2 data update

JL1015E: Gene by gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

JL1016E: Health-related quality of life (HRQoL) and pain in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

JL1017E: Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Subgroup Analysis from the Phase 3 HERO Study

JL1018E: Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)

JL1021E: Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis from the Randomized Phase 3 HERO Study

JL1022E: Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis

JL1023E: Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC)

JL1024E: Patient Identification for Chimeric Antigen Receptor T-Cell Therapy: Initial Insights From the CARTITUDE Program in Multiple Myeloma

JL1025E: Phase 3 multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder

JL1028E: PRIMARY RESULTS OF SUBCUTANEOUS EPCORITAMAB DOSE EXPANSION IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A PHASE 2 STUDY

JL1029E: Reasons for Oncologist and Urologist Treatment Choice in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Physician Survey Linked to Patient Chart Reviews in the United States

JL1030E: Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)

JL1031E: Risk and Management of Intracranial Progression on Amivantamab in Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion (ex20ins)-mutated Non-small Cell Lung Cancer (NSCLC)

JL1032E: Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis

JL1033E: Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): update from phase 1/2 trial

JL1034E: SunRISe-1: phase 2b study of TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy

JL1035E: The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States: A Cost of Care and Budget Impact Model of Venetoclax plus Obinutuzumab Sequences for CLL Patients

JL1036E: The Efficacy of Enzalutamide (ENZA) Plus Androgen Deprivation Therapy (ADT) on Oligometastatic Hormone-Sensitive Prostate Cancer: Extended Post Hoc Analysis of ARCHES

JL1038E: Treatment Duration and Long-term Outcomes With Daratumumab in Transplant-ineligible Newly Diagnosed Multiple Myeloma From the Phase 3 MAIA Study

JL1039E: Tumor agnostic efficacy and safety of erdafitinib in patients with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis results

JL1041E: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)